NCT04667637View on ClinicalTrials.gov

Improving Neuroprotective Strategy for Ischemic Stroke With Sufficient Recanalization After Thrombectomy by Edaravone Dexborneol

PHASE2CompletedINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

February 23, 2021

Primary Completion Date

October 10, 2022

Study Completion Date

October 10, 2022

Conditions

StrokeEndovascular Thrombectomy

Interventions

DRUG

edaravone dexborneol

Intravenous injections of edaravone dexborneol (37.5mg, dissolved in 100ml saline) twice a day for 12 ±2 days.

Trial Locations (1)

110840

General Hospital of Northern Theater Command, Shenyang

All Listed Sponsors

lead

Hui-Sheng Chen

OTHER

NCT04667637 - Improving Neuroprotective Strategy for Ischemic Stroke With Sufficient Recanalization After Thrombectomy by Edaravone Dexborneol | Biotech Hunter | Biotech Hunter